CENOBAMATE (cenobamate) by SK Life Science is partial-onset seizures is unknown. Approved for partial-onset seizures in adult patients.
Drug data last refreshed 1mo ago
partial-onset seizures is unknown. Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA A ) ion channel.
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Cenobamate in Adults With Focal-Onset Seizures
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
Worked on CENOBAMATE at SK Life Science? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.